Eledon Pharmaceuticals (NASDAQ:ELDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Pharmaceuticals (NASDAQ:ELDN) had its price target lowered by analysts at Guggenheim from $9.00 to $8.00. They now have a "buy" rating on the stock.